The structure of the active component of hematoporphyrin derivative.
The structure of the active component of hematoporphyrin derivative.
复制标题
血卟啉衍生物活性成分的结构。
DOI：
10.1007/978-1-4684-4721-7_3
复制
发表时间：
1984
期刊：
影响因子：
--
通讯作者：
K. R. Weishaupt
中科院分区：
文献类型：
--
作者：
T. Dougherty;W. Potter;K. R. Weishaupt
利用血卟啉衍生物（Hpd）作为光敏剂的光放射治疗（PRT）在恶性肿瘤的局部治疗中正在美国的几个中心进行临床试验。S.国内外这种疗法是基于Hpd在大多数肿瘤中的定位和保留，以及其光动力作用，其可能至少作为第一步产生单线态氧。迄今为止，在超过1500名接受HPD的患者中遇到的唯一药物毒性是全身性光敏性，这要求患者避免强光，特别是阳光，持续30天或更长时间。虽然这种毒性是可以避免的，但它存在将PRT用于非卧床和活动患者的早期疾病的缺点。
Photoradiation therapy (PRT) for local treatment of malignant tumors utilizing hematoporphyrin derivative (Hpd) as photosensitizing drug is undergoing clinical trials in several centers in the U. S. and abroad. This therapy is based on the localization and retention of Hpd in most tumors, as well as its photodynamic action which likely generates singlet oxygen at least as a first step. The only drug toxicity encountered to date in over 1500 patients receiving Hpd has been a generalized photosensitivity which requires patients to avoid bright light, especially sunlight, for 30 days or more. While this toxicity is avoidable it presents a drawback to utilizing PRT for early stage disease in ambulatory and active patients.
卟啉制剂血卟啉衍生物的肿瘤定位成分。
影响因子：
11.2
作者：
Kessel,D;Chou,TH
通讯作者：
Chou,TH